Vortioxetine (Trintellix)
What studies of Vortioxetine (Trintellix) found
At a glance, by condition
Long COVID: C Mixed results
Based on the strongest evidence, the placebo trial and compared with another group, not randomised and studies with no comparison group and randomised trials and placebo trials (very low certainty): 16 of 17 findings are C.
10 outcomes rated · see each below
How we got this
Each condition’s headline comes from its graded findings (one for each outcome and kind of study) rated with the highest certainty: the grade most of them share; a tie goes to the finding with the most people, then the most studies, then the outcome’s name. It sums up the grades below, and conditions are never combined.
What this means: Studies of Vortioxetine (Trintellix) for long COVID disagree, so it’s not clear whether it helps. If you’re thinking about it, talk it through with a doctor who knows ME/CFS or long COVID.
Ask about this treatment
The grades, in plain words
Each outcome gets a direction, a certainty and a letter read from the two. Certainty is judged with GRADE, the method Cochrane and WHO use.
- AHelpsImprovement, high certaintyProbably helpsImprovement, moderate certainty
- BMay helpImprovement, low certainty
- Vortioxetine (Trintellix) · Long COVID is hereCMight help, very uncertainImprovement, very low certaintyMixed resultsStudies disagree
- DLittle or no differenceStudies found little or no difference
- FHarmsIt made things worse
By symptom and daily life
Long COVID
Symptoms
Cognition (brain fog)4 studies · 268 people took Vortioxetine (Trintellix) Mixed results C
Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (296 in all); the studies disagree.
Placebo trials2 studies · 296 people with results
Studies disagree about cognition (brain fog).
Studies disagree about whether vortioxetine (Trintellix) helps cognition (brain fog). Mixed results · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (296 in all)
- The studies disagree
Compared with another group, not randomised140 in the study · over 8 weeks · 10-20 mg/d
Cognition (brain fog) improved more than in the comparison group.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on cognition (brain fog) in long COVID. Improvement · very low certainty C
- Serious risk of bias (ROBINS-I)
Studies with no comparison group50 in the study · three-months treatment · 10-20 mg/d, flexibly dosed
Cognition (brain fog) improved.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on cognition (brain fog) in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 4 studies
-
- People in the study
- 200 randomised · 147 started
- Dose
- 5–20 mg, daily
- Outcome
- change in Digit Symbol Substitution Test (DSST) scores from baseline to the endpoint Digit Symbol Substitution Test (DSST)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
Vortioxetine for the Treatment of Post-COVID-19 Condition: A Randomized Controlled Trial (S28.001) (2024) abstract
- People in the study
- 200 randomised · 149 started
- Dose
- 5–20 mg, daily for 8 weeks of double-blind treatment
- Outcome
- change from baseline-to-endpoint in the Digit Symbol Substitution Test (DSST) Digit Symbol Substitution Test
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- High
-
- People in the study
- 140 in the study
- Dose
- 10-20 mg/d
- Outcome
- Digital Symbol Substitution Test (DSST) Digital Symbol Substitution Test
- Effect
- better
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- NI. how the comparison group was chosen isn't reported
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- NI. missing data aren't reported
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Moderate. a pre-specified primary outcome
-
- People in the study
- 50 in the study
- Dose
- 10-20 mg/d, flexibly dosed
- Outcome
- PDQ-D5 Perceived Deficits Questionnaire for Depression
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Depression5 studies · 260 people took Vortioxetine (Trintellix) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (149 in all).
The placebo trial200 randomised · 149 started · 8 weeks · 5–20 mg, daily for 8 weeks of double-blind treatment
Depression improved more than in the comparison group.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on depression in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (149 in all)
Compared with another group, not randomised140 in the study · over 8 weeks · 10-20 mg/d
Depression improved more than in the comparison group.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on depression in long COVID. Improvement · very low certainty C
- Serious risk of bias (ROBINS-I)
Studies with no comparison group3 studies · 115 people with results
Depression improved.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on depression in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 5 studies
-
Vortioxetine for the Treatment of Post-COVID-19 Condition: A Randomized Controlled Trial (S28.001) (2024) abstract
- People in the study
- 200 randomised · 149 started
- Dose
- 5–20 mg, daily for 8 weeks of double-blind treatment
- Outcome
- depressive symptoms
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 140 in the study
- Dose
- 10-20 mg/d
- Outcome
- Montgomery-Asberg Depression Rating Scale (MADRS) Montgomery-Asberg Depression Rating Scale
- Effect
- better
- Risk of bias
ROBINS-I: Serious
- Confounding
- NI. adjustment for confounding isn't reported
- Selection of participants
- NI. how the comparison group was chosen isn't reported
- Classification of interventions
- Low. assigned and recorded at the start
- Deviations from intended interventions
- NI. not reported for this design
- Missing data
- NI. missing data aren't reported
- Measurement of outcomes
- Serious. self-reported by people who knew their treatment
- Selection of the reported result
- Moderate. a pre-specified secondary outcome
-
- People in the study
- 80 in the study · 65 with outcome data
- Dose
- 5–20 mg/day, flexibly dosed
- Outcome
- mood relapse
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
- People in the study
- 50 in the study
- Dose
- 10-20 mg/d, flexibly dosed
- Outcome
- HDRS total score Hamilton Depression Rating Scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
Post-COVID syndrome or persistent COVID and depression (2023)
- People in the study
- —
- Dose
- 10mg
- Outcome
- depressive mood
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Low mood or anxiety3 studies · 99 people took Vortioxetine (Trintellix) Mixed results C
Why this grade: Mixed results, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; one trial of 64 people found no clear difference; a small benefit can't be ruled out; inconsistency: 2 studies without a placebo group found improvement.
The placebo trial200 randomised · 64 analysed · over an eight-week period · Individuals ages 18 to 64 received 10mg for the first two weeks. The dose was titrated to 20mg from week three to week eight
No clear difference in low mood or anxiety.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on low mood or anxiety in long COVID. Little or no difference · very low certainty D
- High risk of bias (RoB 2) in the results that carry most of the weight
- One trial of 64 people found no clear difference; a small benefit can't be ruled out
Studies with no comparison group2 studies · 65 people with results
Low mood or anxiety improved.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on low mood or anxiety in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Not all results were tested against chance
See the 3 studies
-
A Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Effectiveness of Vortioxetine in Treating Reward Dysfunction Among Individuals with Post COVID-19 Condition (2023)
- People in the study
- 200 randomised · 64 analysed
- Dose
- Individuals ages 18 to 64 received 10mg for the first two weeks. The dose was titrated to 20mg from week three to week eight
- Outcome
- SHAPS total score Snaith-Hamilton Pleasure Scale
- Effect
- no clear difference
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- Low
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 80 in the study · 65 with outcome data
- Dose
- 5–20 mg/day, flexibly dosed
- Outcome
- SHAPS Snaith-Hamilton Pleasure Scale
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
-
Post-COVID syndrome or persistent COVID and depression (2023)
- People in the study
- —
- Dose
- 10mg
- Outcome
- apathy
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Sleep1 study · 65 people took Vortioxetine (Trintellix) Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design).
Studies with no comparison group80 in the study · 65 with outcome data · at baseline and after 1 and 3 months of treatment (endpoint) · 5–20 mg/day, flexibly dosed
Sleep improved.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on sleep in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 1 study
-
- People in the study
- 80 in the study · 65 with outcome data
- Dose
- 5–20 mg/day, flexibly dosed
- Outcome
- PSQI Pittsburgh Sleep Quality Index
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Anxiety1 study Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.
Studies with no comparison group1 study · In the following months · 10mg (few people)
Anxiety improved.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on anxiety in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 1 study
-
Post-COVID syndrome or persistent COVID and depression (2023)
- People in the study
- —
- Dose
- 10mg
- Outcome
- anxious symptoms
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Breathlessness1 study Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.
Studies with no comparison group1 study · In the following months · 10mg (few people)
Breathlessness improved.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on breathlessness in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 1 study
-
Post-COVID syndrome or persistent COVID and depression (2023)
- People in the study
- —
- Dose
- 10mg
- Outcome
- dyspnea
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Fatigue1 study Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.
Studies with no comparison group1 study · In the following months · 10mg (few people)
Fatigue improved.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on fatigue in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 1 study
-
Post-COVID syndrome or persistent COVID and depression (2023)
- People in the study
- —
- Dose
- 10mg
- Outcome
- asthenia
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Pain1 study Improvement C
Why this grade: Improvement, very low certainty, from studies without a control group: no control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design); few people, or how many isn't reported; not all results were tested against chance.
Studies with no comparison group1 study · In the following months · 10mg (few people)
Pain improved.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on pain in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
- Few people, or how many isn't reported
- Not all results were tested against chance
See the 1 study
-
Post-COVID syndrome or persistent COVID and depression (2023)
- People in the study
- —
- Dose
- 10mg
- Outcome
- arthromyalgia
- Effect
- better (not tested)
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily life and health overall
Quality of life3 studies · 287 people took Vortioxetine (Trintellix) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (296 in all).
Randomised trials2 studies · 296 people with results
Quality of life improved more than in the comparison group.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on quality of life in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (296 in all)
Studies with no comparison group80 in the study · 65 with outcome data · at baseline and after 1 and 3 months of treatment (endpoint) · 5–20 mg/day, flexibly dosed
Quality of life improved.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on quality of life in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 3 studies
-
Vortioxetine for the Treatment of Post-COVID-19 Condition: A Randomized Controlled Trial (S28.001) (2024) abstract
- People in the study
- 200 randomised · 149 started
- Dose
- 5–20 mg, daily for 8 weeks of double-blind treatment
- Outcome
- HRQoL health-related quality of life
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- Some concerns
-
- People in the study
- 147 analysed
- Dose
- —
- Outcome
- between-group difference in mean change of WHO-5 total scores (after adjusting for the type of cognitive test) World Health Organization Wellbeing Scale 5-item
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- Some concerns
- Deviations from intended interventions
- High
- Missing outcome data
- High
- Measurement of the outcome
- High
- Selection of the reported result
- Some concerns
-
- People in the study
- 80 in the study · 65 with outcome data
- Dose
- 5–20 mg/day, flexibly dosed
- Outcome
- WHO-5 World Health Organization-Five Well-Being Index
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Daily functioning2 studies · 123 people took Vortioxetine (Trintellix) Improvement C
Why this grade: Improvement, very low certainty, from randomised trials: high risk of bias (RoB 2) in the results that carry most of the weight; few people (144 in all).
The placebo trial200 randomised · 147 started · 144 analysed · 8 weeks · 5 to 20 mg per day, age-dependent titration over 8 weeks
Daily functioning improved more than in the comparison group.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on daily functioning in long COVID. Improvement · very low certainty C
- High risk of bias (RoB 2) in the results that carry most of the weight
- Few people (144 in all)
Studies with no comparison group50 in the study · three-months treatment · 10-20 mg/d, flexibly dosed
Daily functioning improved.
The evidence is very uncertain about the effect of vortioxetine (Trintellix) on daily functioning in long COVID. Improvement · very low certainty C
- No control group: part of any change may be placebo, natural recovery or regression to the mean (risk of bias by design)
See the 2 studies
-
- People in the study
- 200 randomised · 147 started · 144 analysed
- Dose
- 5 to 20 mg per day, age-dependent titration over 8 weeks
- Outcome
- SDS subcategories at treatment endpoint Sheehan Disability Scale (SDS)
- Effect
- better
- Risk of bias
RoB 2: High
- Randomisation process
- High
- Deviations from intended interventions
- Low
- Missing outcome data
- High
- Measurement of the outcome
- Low
- Selection of the reported result
- High
-
- People in the study
- 50 in the study
- Dose
- 10-20 mg/d, flexibly dosed
- Outcome
- MCS Mental Component Score
- Effect
- better
- Risk of bias
- before-after study without a control group (JBI checklist for quasi-experimental studies); not rated with RoB 2 or ROBINS-I
Studies of combinations
Outcomes that only studies of Vortioxetine (Trintellix) given together with other treatments looked at. Shown, not graded: they can’t tell what Vortioxetine (Trintellix) did alone.
Fatigue ME/CFS
Combination: Vortioxetine (Trintellix)1 in the study
P149: Chronic fatigue syndrome and its response to the use of a multimodal antidepressant (2023): treatment of Chronic Fatigue Syndrome, better (not tested).
Shown, not counted: Vortioxetine (Trintellix) was given together with other treatments.
Pain ME/CFS
Combination: Vortioxetine (Trintellix)1 in the study
P149: Chronic fatigue syndrome and its response to the use of a multimodal antidepressant (2023): control of concomitant pain, better (not tested).
Shown, not counted: Vortioxetine (Trintellix) was given together with other treatments.
Daily functioning ME/CFS
Combination: Vortioxetine (Trintellix)1 in the study
P149: Chronic fatigue syndrome and its response to the use of a multimodal antidepressant (2023): functional state, better (not tested).
Shown, not counted: Vortioxetine (Trintellix) was given together with other treatments.
Side effects
Stopping because of side effects2 studies
Only 6 patients (7.5%) reported mild side effects at one month, i.e., nausea (5%, n=4), headache (1.25%, n=1), and dry mouth (1.25%, n=1), which gradually disappeared over time, and no one needed to discontinue vortioxetine because of tolerability concerns.
Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes. (2023)The percentage of persons who discontinued treatment were 3% (n = 4) and 0% (n = 0) for the vortioxetine and placebo group, respectively
Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial. (2024)
Side effects studies reported3 kinds
| Side effect | Studies that reported it |
|---|---|
| Anxiety or irritability | 1 study |
| Headache | 1 study |
| Nausea or stomach upset | 1 study |
Doses studied
What researchers used, as the papers print it; not a recommendation.
- 1Start
5 to 10 mg at the start in most studies
- 2Raise
Raised step by step in 10 of 11 studies
- 3Top dose
Most often 20 mg (10 of 11 studies)
Doses across 11 studies
5 to 20 mg.
Each study’s dose, as printed
- 5–20 mg, daily Impacts of Metabolic Disruption, Body Mass Index and Inflammation on Cognitive Function in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine (P6-10.009) (2025)
- 5–20 mg/day (10 mg/day weeks 1–2, 20 mg/day weeks 3–8; 5 mg/day then 10 mg/day for participants aged 65 and older), daily for 8 weeks Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine. (2024)
- 10-20 mg/d, flexibly dosed Cognitive impairment in post-covid-19 patients with major depressive episodes – a three-months study on the effect of vortioxetine (2022)
- 5–20 mg/day, flexibly dosed Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes. (2023)
- 10 mg/day during Weeks 1 and 2, and 20 mg/day from Weeks 3–8 (ages 18–65); 5 mg/day during Weeks 1 and 2 and 10 mg/day from Weeks 3–8 (65+), daily for 8 weeks of double-blind treatment; down titration to the index dose permitted for participants unable to tolerate higher doses Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial. (2024)
- 5–20 mg/day Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine. (2024)
- 5 to 20 mg per day, age-dependent titration over 8 weeks Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis. (2024)
- 10-20 mg/d Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome: Real-World Evidence. (2025)
- 10mg Post-COVID syndrome or persistent COVID and depression (2023)
- Individuals ages 18 to 64 received 10mg for the first two weeks. The dose was titrated to 20mg from week three to week eight A Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Effectiveness of Vortioxetine in Treating Reward Dysfunction Among Individuals with Post COVID-19 Condition (2023)
- 5–20 mg, daily for 8 weeks of double-blind treatment Vortioxetine for the Treatment of Post-COVID-19 Condition: A Randomized Controlled Trial (S28.001) (2024)
All papers
- Impacts of Metabolic Disruption, Body Mass Index and Inflammation on Cognitive Function in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine (P6-10.009)2025 · placebo trial · 200 randomised · 147 started · abstract
Summary
This 8-week randomized, double-blind, placebo-controlled trial was conducted in adults aged 18 and older in Canada with WHO-defined Post-COVID-19 Condition (PCC) symptoms. The study aimed to investigate the efficacy of vortioxetine in improving cognitive deficits in individuals with Post-COVID-19 Condition (PCC), while accounting for the interaction of metabolic dysfunction, elevated inflammation, and body mass index (BMI). A total of 200 individuals were enrolled, and 147 were randomized in a 1:1 ratio to vortioxetine (5–20 mg, n = 73) or placebo (n = 74) for daily treatment under double-blind conditions. The primary outcome measure was the change in Digit Symbol Substitution Test (DSST) scores from baseline to the endpoint. The between-group analysis demonstrated a significant improvement with vortioxetine at the endpoint (mean difference = 0.621, SEM = 0.313, p = 0.047). The text also reports significant effects for treatment (χ 2 = 7.583, p = 0.006) and the treatment x time x CRP x TG-HDL x BMI interaction (χ 2 = 11.967, p = 0.018) on cognitive function. Harms and the number analysed were not reported. The text does not state limitations.
- Impacts of metabolic disruption, body mass index and inflammation on cognitive function in post-COVID-19 condition: a randomized controlled trial on vortioxetine.2024 · placebo trial · 200 randomised · 147 started · 147 analysed
Summary
This was a post-hoc analysis of an 8-week randomized, double-blind, placebo-controlled trial in adults aged 18 years and older in Canada with WHO-defined post-COVID-19 condition. Recruitment ran from November 2021 to January 2023. A total of 200 individuals were enrolled, and 147 were randomized 1:1 to vortioxetine (5–20 mg, n = 73) or placebo (n = 74); the ITT analysis included 147. The primary outcome was change in the Digit Symbol Substitution Test (DSST) score from baseline to endpoint. At the 8-week endpoint, the between-group analysis showed a significant difference in overall change in favour of vortioxetine (mean difference = 0.621, SEM = 0.313, p = 0.047). Within-group change in DSST scores was significant for vortioxetine (mean difference = 1.933, SEM = 0.594, p = 0.001) and not significant for placebo (mean difference = 0.289, SEM = 0.171, p = 0.091). The text does not report side effects or withdrawals due to harms. The authors describe the analysis as post-hoc and note limitations in establishing causal relationships and temporal sequence.
- Vortioxetine for the treatment of post-COVID-19 condition: a randomized controlled trial.2024 · placebo trial · 200 randomised · 149 started · 149 analysed
Summary
This 8-week randomized, double-blind, placebo-controlled study enrolled adults ≥18 years in Canada with WHO-defined post-COVID-19 condition and a history of confirmed SARS-CoV-2 infection. Of 200 enrolled, 149 were randomized to vortioxetine (5–20 mg, n=75) or placebo (n=74) daily for 8 weeks. The primary outcome was change from baseline to end point on the Digit Symbol Substitution Test (DSST); secondary outcomes included the Quick Inventory of Depressive Symptomatology 16-item (QIDS-SR-16) and WHO Wellbeing Scale 5-item (WHO-5). A total of 68 (90.7%) vortioxetine and 73 (98.6%) placebo participants completed all 8 weeks (P=0.089). The unadjusted between-group DSST change was not significant [P=0.361, 95% CI (−0.179, 0.492)]. In an adjusted model, a between-group difference was reported [P=0.028, 95% CI (0.029, 0.492)], and a treatment × time interaction with baseline CRP as moderator was reported (P=0.012); in participants with baseline CRP above the mean, DSST improvement was reported (P=0.045). For QIDS-SR-16, the between-group mean difference was −1.516 [95% CI (−2.847, −0.185), P=0.026]; for WHO-5 it was 2.356 [95% CI (0.774, 3.938), P=0.004]. Treatment-emergent adverse events were reported in 26.8% (n=40 of 149) with vortioxetine and 22.1% (n=33 of 149) with placebo. The percentage who discontinued treatment were 3% (n=4) and 0% (n=0), respectively; Fig. 1 lists 7 vortioxetine drop-outs (4 due to side effects, 3 personal issues) and 1 placebo drop-out due to personal issues. The authors state the study was underpowered to detect a between-group separation from placebo at Week 8 using the DSST.
- Assessing the Effects of Metabolic Disruption, Body Mass Index and Inflammation on Depressive Symptoms in Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine.2024 · placebo trial · 200 randomised · 147 started · 147 analysed
Summary
This post hoc analysis of an 8-week randomized, double-blind, flexible-dosed, placebo-controlled trial asked whether vortioxetine improves depressive symptoms in adults with WHO-defined post-COVID-19 condition (PCC) in Canada. Of 200 participants enrolled, 147 were randomized to vortioxetine (5–20 mg/day, n = 73) or placebo (n = 74) for daily treatment. The primary measure was change from baseline to endpoint on the 16-Item Quick Inventory of Depressive Symptomatology Self-Report Questionnaire (QIDS-SR-16). In the adjusted model, the vortioxetine group showed a within-group change of -4.93 (SEM 0.903, p < 0.001); the placebo group change was -0.41 (SEM 1.207, p = 0.734). The between-group difference at the 8-week endpoint was -5.41 (SEM 1.335, p < 0.001) in favor of vortioxetine. The adjusted model also reported time (v2 = 9.601, p = 0.002), treatment (v2 = 9.135, p = 0.003), and treatment x time x CRP x TG-HDL x BMI interaction (v2 = 26.092, p < 0.001) effects. Harms, side effects and withdrawals were not reported. The authors state the analysis was post hoc, the inflammation/metabolic/BMI association was not pre-specified, depressive symptoms were self-reported, and the sample was heterogeneous.
- Impact of vortioxetine on psychosocial functioning moderated by symptoms of fatigue in post-COVID-19 condition: a secondary analysis.2024 · placebo trial · 200 randomised · 147 started · 144 analysed
Summary
This secondary analysis of a double-blind, randomized, flexible-dosed, placebo-controlled study conducted across Canada examined vortioxetine for psychosocial functioning in people with post-COVID-19 condition (PCC) meeting WHO criteria. Participants were randomly assigned 1:1 to vortioxetine (5 to 20 mg per day) or placebo for 8 weeks. The paper states 200 participants completed written consent; 147 were the intent-to-treat population, and 144 were included in this post hoc analysis. Table 1 lists 74 placebo and 73 vortioxetine participants. Outcomes were the Sheehan Disability Scale (SDS) and Fatigue Severity Scale (FSS). The abstract reports a significant between-group difference at treatment endpoint in the family, social, and work SDS subcategories (p < 0.001). Between-group mean differences from baseline to endpoint were −0.86 for SDS social (p = 0.048), −0.95 for work (p = 0.016), and −0.92 for family (p = 0.028). Within-group improvements were reported for vortioxetine and placebo. The authors report that improvement in psychosocial function was significantly mediated by improvement in fatigue. Side effects and withdrawals due to harms were not reported in this text.
- Vortioxetine for the Treatment of Post-COVID-19 Condition: A Randomized Controlled Trial (S28.001)2024 · placebo trial · 200 randomised · 149 started · abstract
Summary
This was an 8-week randomized, double-blind, placebo-controlled study of vortioxetine for Post-COVID-19 Condition (PCC). Participants were adults ≥ 18 years old residing in Canada with World Health Organization (WHO)-defined PCC symptoms and a history of confirmed SARS-CoV-2 infection. Of the 200 participants enrolled, 149 participants were randomized (1:1) to receive vortioxetine (5–20 mg, n = 75) or placebo (n = 74) daily for 8 weeks of double-blind treatment. The primary outcome was the change from baseline-to-endpoint in the Digit Symbol Substitution Test (DSST); secondary outcomes included changes from baseline-to-endpoint in the Quick Inventory of Depressive Symptomatology-16-item (QIDS-SR16) and World Health Organization Wellbeing Scale-5-item (WHO-5). A total of 68 (90.7%) participants randomized to vortioxetine and 73 (98.6%) participants randomized to placebo completed all 8 weeks. Between-group analysis did not show a significant difference in the overall change in cognitive function (p = 0.361, 95% CI [−0.179, 0.492]). In the adjusted model, a significant treatment-by-time interaction was observed in favor of vortioxetine treatment with baseline c-reactive protein (CRP) as a moderator (p = 0.012). Significant improvement was obtained in measures of depressive symptoms (p < 0.001) and HRQoL (p < 0.001) in vortioxetine-treated participants and between the treatment groups (depressive symptoms: p = 0.026; HRQoL: p = 0.004). Harms were not reported in the text provided.
- A Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Effectiveness of Vortioxetine in Treating Reward Dysfunction Among Individuals with Post COVID-19 Condition2023 · placebo trial · 200 randomised · 64 analysed
Summary
This randomized, double-blind, placebo-controlled study asked whether vortioxetine would improve reward dysfunction in adults with WHO-defined long COVID. Participants were recruited from the general public, mostly through Long Haulers Canada. A total of 200 participants were recruited for the primary study; 64 were included in the final analysis, of which 30 received placebo and 34 received vortioxetine. Five participants were excluded because they did not complete the week 8 EEfRT assessment. Adults ages 18 to 64 received vortioxetine 10mg for the first two weeks, then 20mg from week three to week eight; the comparison was placebo. The main measure was hard-task selection on the Effort Expenditure for Rewards Task (EEfRT), with the Snaith-Hamilton Pleasure Scale (SHAPS) as a secondary measure, over an eight-week period. The study reported no significant effect of treatment group on hard-task selection (𝞆2=0.175, p=0.675) and no significant visit type X treatment group interaction (𝞆2=0.138, p=0.711). Placebo hard-task selection was 63% at baseline and 66% at endpoint; vortioxetine was 66% and 67%. Mean SHAPS scores were similar: placebo 12.03 at baseline and 12.43 at endpoint; vortioxetine 12.47 and 12.85; treatment group effect was not significant (𝞆2=0.875, p=0.350). Win probability and reward magnitude were associated with hard-task selection (𝞆2=117.9, p<0.001; 𝞆2=103.3, p<0.001). Side effects and withdrawals due to harms were not reported.
- The Impact of Cognitive Function on Health-Related Quality of Life in Persons with Post-COVID-19 Condition: A Randomized Controlled Trial on Vortioxetine (S19.003)2025 · randomised trial · 147 analysed · abstract
Summary
This randomized controlled trial examined vortioxetine versus placebo in individuals with post-COVID-19 condition (PCC). The objective was to investigate the effects of cognitive function on health-related quality of life (HRQoL) and whether vortioxetine modulates the relationship between cognitive function and HRQoL. Participants aged 18–65 years were randomized to receive either vortioxetine or placebo for 8 weeks. The setting was not reported in the abstract. HRQoL was assessed using the World Health Organization Wellbeing Scale 5-item; cognitive function was measured using the Digit Symbol Substitution Test and the Trail-Making Test A/B. The abstract reports that 147 participants (75.5% females) were included. A significant interaction among treatment, time, and combined DSST z-scores on changes in overall WHO-5 total scores was observed (χ 2 = 15.481, p = 0.004). After adjusting for the type of cognitive test, a significant between-group difference was noted (mean change = 1.77, SEM = 0.868, p = 0.042), favoring vortioxetine. Harms, withdrawals, and the number of participants per arm were not reported in the abstract. People who worsened or stopped were not reported. The authors state that future studies should explore pro-cognitive therapeutic strategies. Limitations were not stated in the abstract.
- Vortioxetine for Cognitive Impairment in Major Depressive Disorder During Post-COVID Syndrome: Real-World Evidence.2025 · compared with another group · 140 in the study
Summary
This prospective, open-label comparative study was carried out at 1 clinical site in people with post-COVID syndrome and new-onset major depressive disorder. A total of 140 participants were assigned to receive vortioxetine (n = 70), escitalopram (n = 36), or sertraline (n = 34) over 8 weeks. Vortioxetine was given at 10-20 mg/d, escitalopram at 10-20 mg/d, and sertraline at 50-200 mg/d. The primary outcome was change from baseline to end point in the Digital Symbol Substitution Test (DSST); secondary outcomes were change in the Montgomery-Asberg Depression Rating Scale (MADRS) and the Patient Reported Outcome Measurement Information System Fatigue Short Form 7a (PROMIS 7a). For DSST, participants assigned to vortioxetine showed significant changes from baseline to end point compared with escitalopram (least squares [LS] mean difference 8.25; 95% CI 6.25-10.25; P < .001) and sertraline (LS mean difference 8.00; 95% CI 5.95-10.06; P < .001). For total MADRS, the vortioxetine group showed significantly greater changes than escitalopram (LS mean difference -4.06; 95% CI -4.92 to -3.20; P < .001) and sertraline (LS mean difference -3.94; 95% CI -4.83 to -3.06; P < .001). Side effects, withdrawals, worsening, and the number analysed were not reported in the abstract. The authors state that vortioxetine has a significant procognitive effect and that antidepressant effects and improvement in fatigue symptoms (PROMIS 7a) also were observed. No limitations are stated in the abstract.
- Impact of vortioxetine on depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition: A secondary analysis.2024 · no comparison group
Summary
This is a secondary analysis published on 2024-06-28 concerning vortioxetine for depressive symptoms moderated by symptoms of anxiety in persons with post-COVID-19 condition. The available text does not report the number of people enrolled, started, or analysed, nor the setting, follow-up duration, trial registration, or comparison groups. It does not report any treatment arms, randomised design, blinding, allocation concealment, or handling of missing data. No results are reported in the available text: there are no between-group results, no before-versus-after treatment results, no patient ratings of treatment, and no harms, side-effect counts, or withdrawals attributed to harms. The text gives no authors' conclusion or stated limitations. Because the available text is limited to publication metadata and references, no findings about vortioxetine can be recorded for this study from the text provided.
- Vortioxetine improves physical and cognitive symptoms in patients with post-COVID-19 major depressive episodes.2023 · no comparison group · 80 in the study · 65 with outcome data
Summary
This retrospective, open-label, observational study evaluated vortioxetine in 80 patients with post-COVID-19 major depressive episodes referred to Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS in Rome. Patients received vortioxetine 5–20 mg/day, flexibly dosed, with assessments at baseline and after 1 and 3 months of treatment (endpoint); 65 patients had endpoint data. There was no comparison group. Outcomes included HDRS, HARS, SF-36, DSST, PDQ-D5, and inflammatory indexes. HDRS mean change was −6.28 at 1 month and −13.29 at 3 months (p<0.001); HDRS physical symptoms changed by −2.89 and −5.37 (p<0.001); DSST changed by 4.06 (p=0.023) and 7.18 (p=0.02); PDQ-D5 changed by −3.8 and −6.44 (p<0.001). After one month, 12 (15%) patients were responders and 3 (3.7%) remitters; at endpoint, 57 (87.7%) reached remission, and 2 (3.1%) were non-responders after three months. No patient experienced a mood relapse. The results report 6 patients (7.5%) with mild side effects at one month—nausea (n=4), headache (n=1), and dry mouth (n=1)—which gradually disappeared, and no one needed to discontinue vortioxetine because of tolerability concerns; the discussion states the absence of adverse effects and treatment dropouts. The authors state limitations including the monocentric setting, open-label retrospective observational design, partial consideration of confounding variables, and lack of a control group.
- Post-COVID syndrome or persistent COVID and depression2023 · no comparison group
Summary
This case report describes a man who developed persistent symptoms after severe COVID-19 — post-COVID syndrome — and was followed in Mental Health. He received antidepressant treatment with Vortioxetine 10mg. There was no comparison group; the report describes his course before and after starting treatment. In the following months the authors report significant improvement: decrease of the asthenia, dyspnea, arthromyalgia, and especially anxious symptoms and depressive mood. Apathy, anhedonia and suicidal ideation disappeared. Memory failures persisted, remaining in a similar degree or with slight subjective improvement. Harms and side effects were not reported. The authors state it is difficult to discern the origin of the symptoms, not being able to differentiate an adaptive difficulty to the infection situation versus a more organic affectation. They conclude that the etiopathogenesis of the syndrome is of interest. As a case report with no comparison group, the report cannot separate treatment effects from the natural course.
- Cognitive impairment in post-covid-19 patients with major depressive episodes – a three-months study on the effect of vortioxetine2022 · no comparison group · 50 in the study
Summary
This retrospective study included fifty patients with post-COVID-19 major depressive episodes treated with vortioxetine (10-20 mg/d, flexibly dosed) and evaluated at baseline and after three-months treatment; there was no comparison group. Cognitive symptomatology and functioning were measured with the Perceived Deficits Questionnaire for Depression (PDQ-D5), Digit Symbol Substitution Test (DSST), and SF-36 Mental Component Score (MCS); depressive symptoms were measured with the Hamilton Depression Rating Scale (HDRS). From baseline to endpoint, PDQ-D5 scores changed from 10 Æ 4.91 to 4.81 Æ 2.95 (p < 0.001), DSST from 41.6 Æ 12.6 to 55.7 Æ 17.9 (p ¼ 0.004), MCS from 33 Æ 10.6 to 45.5 Æ 12 (p ¼ 0.019), and HDRS total from 17.8 Æ 4.23 to 5.92 Æ 3.45 (p ¼ 0.007). Harms and withdrawals were not reported. The authors describe these as preliminary results and state that further studies with larger samples are needed to confirm the findings.
- P149: Chronic fatigue syndrome and its response to the use of a multimodal antidepressant2023 · combination: given with other treatments · 1 in the study
- Systematic review of interventions for mental health, cognition and psychological well-being in long COVID.2024 · systematic review
Summary
This systematic review aimed to identify and synthesise publicly available research testing treatments for mental health, cognition and psychological well-being in long COVID. It included 33 documents representing 31 studies and 2477 participants recruited across four continents. The studies covered 7 psychosocial, 5 pharmaceutical, 3 natural supplement, 9 neurocognitive, 2 physical rehabilitation and 5 integrated intervention studies; 11 were RCTs, 2 non-randomised controlled trials, 10 uncontrolled trials, 7 case studies or series and 1 qualitative study. Some controlled trials reported significant group×time interactions: vortioxetine for depression and health-related QoL but not cognition; hyperbaric oxygen for total cognition and psychological distress only; high-definition transcranial direct current stimulation for cognitive and psychosocial fatigue, anxiety and QoL; and a programme combining non-invasive cognitive stimulation and guided mindfulness for mental fatigue, anxiety, depression, mood disturbance and several cognitive domains. Other trials reported no significant group×time interaction, including an adaptogen formulation and the ReCOVERY app. Many uncontrolled studies reported significant prepost improvements, but the authors state these cannot be definitively associated with treatment without a control group. Counts of people who worsened or stopped and side-effect counts were not reported in the recorded data; the authors note many studies did not report adverse events.
- Interventions for the management of long covid (post-covid condition): living systematic review.2024 · systematic review
Summary
This living systematic review assessed drug and non-drug interventions for long covid in adults. It included 24 unique trials with 3695 patients, predominantly from the Americas or Europe. One trial (n=114) compared an online CBT programme called “fit after covid” with usual care; moderate certainty evidence suggested CBT probably reduces fatigue (mean difference −8.4, 95% CI −13.11 to −3.69) and probably improves concentration (mean difference −5.2, −7.97 to −2.43). One trial (n=585) compared combined physical and mental health rehabilitation with one session of online advice and support; moderate certainty evidence suggested it probably increases recovery or important improvement (161 more per 1000 patients, 95% CI 61 more to 292 more), improves quality of life (mean difference 0.04, 95% CI 0.00 to 0.08), and reduces depression (mean difference −1.50, −2.41 to −0.59), with little or no effect on physical and cognitive function or anxiety. Intermittent aerobic exercise 3-5 times weekly for 4-6 weeks probably improves physical function compared with continuous exercise (mean difference 3.8, 95% CI 1.12 to 6.48; n=110). Vortioxetine for eight weeks did not improve cognitive function; coenzyme Q10 500 mg/day for six weeks probably did not improve quality of life (n=119); SIM01 might alleviate fatigue (200 more per 1000 patients, 95% CI 94 more to 336 more; n=463) but probably did not improve quality of life. No instances of post-exertional malaise were reported in the rehabilitation trial; effects on serious adverse events were very uncertain.
- Interventions for Long COVID: A Narrative Review.2025 · review
Summary
This narrative review synthesized evidence from 97 studies (n=8260, 103 publications) on interventions for common long COVID symptoms: fatigue, neurocognitive symptoms, anxiety, depression, and sleep issues. The review included randomized and non-randomized studies and compared medications, rehabilitation, behavioral and mind-body programs, supplements, complementary treatments, and COVID-19 vaccination with placebo, usual care, no treatment, or other active comparators. For vortioxetine versus placebo, one RCT (n = 141) reported a significant reduction in depression symptoms (adjMD of −1.52; 95% CI −2.85 to −0.19) and improvement in quality of life (WHO-5, adjMD of 2.36; 95% CI 0.77 to 3.94), with mixed cognitive results. An RCT of “Fit after COVID” CBT (n=114) reported improvement in fatigue (CIS-fatigue: MD −8.8; 95% CI −11.9 to −5.8), cognitive impairment (CIS-concentration: MD −5.1; 95% CI −6.9 to −3.4), and physical function (SF-36-Physical Health: MD 7.1; 95% CI 2.9 to 11.3). Hyperbaric oxygen therapy (n=73) improved fatigue (SF-36 energy subscale, 18.2 vs 6.0, p=0.029) and sleep quality (PSQI, 8.1 vs 9.2, p=0.042) versus sham. Transcranial direct current stimulation (n=47) reduced physical fatigue (MFIS-Physical: p=0.034) but not overall fatigue (MFIS-Total: p=0.184). A COVID-19 vaccine study (n=453) found no statistically significant difference in fatigue, depression, or sleep quality. Adverse events included treatment-related reactions with vortioxetine (26.8% vs. 22.1%), non-serious adverse events with AXA1125 (RR 2.62, 95% CI 1.00 to 6.89), and similar adverse event rates with SIM01 (10% vs. 11%; p=0.63).
- Antidepressants for prevention of severe COVID-19, Long COVID and outlook for other viral diseases2024 · review
Summary
This paper is an Opinion review, not a primary study; it reports no own participants, location, treatment duration, or primary outcome. It summarizes literature found in pubmed as of 09/25/2023: five prospective studies (plus 2 for Long COVID), 7 RCT (plus 2 for Long COVID) and 12 meta-analyses. The review discusses antidepressants for prevention of severe COVID-19 and Long COVID. In its Long COVID table, named entries include fluvoxamine (2 × 50 mg) for Bramante et al. 2022, marked 0; fluoxetine for Farahani et al. 2023, marked (+) Fluoxetine (Fatigue); vortioxetine for Di Nicola et al. 2023, marked +; tricyclic AD for La Sala et al. 2023, marked + Tricyclic AD (2 Cases); AD for Fontera et al. 2022, marked +; SSRI for Rus et al. 2023 (N = 95), marked +; and SSRI for Sidky et al. 2023 (N = 17,933; preprint), marked +. For harms, the review states tolerability of AD was reported to be generally well across prospective, randomized controlled studies and meta-analyses presented in the table. Siripongboonsitti et al. 2023 is noted with no deaths in both the fluvoxamine and control group. The authors describe Long COVID evidence as limited but with first preliminary promising results for AD. The paper itself does not compare arms; it tabulates named studies, including placebo-controlled randomized studies. The recorded data do not report people who worsened or stopped.